Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea · Delayed Price · Currency is KRW 23,950
-1,150 (-4.58%)
At close: Mar 20, 2026
Onconic Therapeutics Revenue
In the year 2025, Onconic Therapeutics had annual revenue of 53.39B KRW with 259.82% growth. Onconic Therapeutics had revenue of 15.58B in the quarter ending December 31, 2025, with 76.28% growth.
Revenue
53.39B
Revenue Growth
+259.82%
P/S Ratio
20.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.08T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.39B | 38.55B | 259.82% |
| Dec 31, 2024 | 14.84B | -6.22B | -29.53% |
| Dec 31, 2023 | 21.06B | 20.96B | 22,064.25% |
| Dec 31, 2022 | 95.00M | 35.00M | 58.33% |
| Dec 31, 2021 | 60.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.40T |
| Chabiotech | 1.20T |
| Hugel | 425.10B |
| Medy-Tox | 241.80B |
| MEDIPOST | 73.59B |
| Pharmicell | 23.94B |
| SillaJen | 7.84B |
| Genomictree | 3.76B |